European Journal of Clinical Pharmacology

, Volume 34, Issue 5, pp 461–464

Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing

  • A. Lindholm
  • S. Henricsson
  • M. Lind
  • R. Dahlqvist


We have measured total and unbound plasma concentrations of cyclosporin A in seven healthy men after single oral doses (12 mg per kg body weight) on two occasions at least two weeks apart.

There was an up to two-fold intraindividual and a more than three-fold interindividual variation in the AUCs of both total and unbound drug.

The intraindividual variability in the AUC of cyclosporin is similar to that of many other drugs and needs to be taken into account in the planning of pharmacokinetic studies.

Key words

cyclosporin A organ transplantation immunosuppression systemic availability plasma concentrations intra-/interindividual variation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Calne RY, White DJG, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Pentlow BD, Rolles K (1978) Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 2: 1323–1327Google Scholar
  2. 2.
    The Canadian Multicentre Transplant Study Group (1983) A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 309: 809–815Google Scholar
  3. 3.
    European Multicentre Trial Group (1982) Cyclosporin A as sole immunosuppressive agent in recipients of kidney allografts from cadaver donors: Preliminary results of a European multicentre trial. Lancet 2: 57–60Google Scholar
  4. 4.
    Cohen DJ, Loertscher R, Rubin MF, Tilney NL, Carpenter CB, Strom TB (1984) Cyclosporine: A new immunosuppressive agent for organ transplantation. Ann Int Med 101: 667–682Google Scholar
  5. 5.
    Beveridge T, Gratwohl A, Michot F, Niederberger W, Nüesch E, Nussbaumer K, Schaub P, Speck B (1981) Cyclosporin A: Pharmacokinetics after a single dose in man and serum levels after multiple dosing in recipients of allogeneic bone-marrow grafts. Curr Ther Res 30: 5–18Google Scholar
  6. 6.
    Robson S, Neuberger J, Keller HP, Abisch E, Niederberger W, von Graffenried B, Williams R (1984) Pharmacokinetic study of cyclosporin A in patients with primary biliary cirrhosis. Br J Clin Pharmacol 18: 627–631Google Scholar
  7. 7.
    Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR (1985) Cyclosporine kinetics in renal transplantation. Clin Pharmacol Ther 38: 296–300Google Scholar
  8. 8.
    Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR (1985) The effect of food on cyclosporine absorption. Transplantation 40: 174–176Google Scholar
  9. 9.
    Bertault-Pérès P, Maraninchi D, Carcassonne Y, Cano JP, Barbet J (1985) Clinical pharmacokinetics of cyclosporin A in bone marrow transplant patients. Cancer Chemother Pharmacol 15: 76–81Google Scholar
  10. 10.
    Burckart GJ, Venkataramanan R, Ptachcinski RJ, Starzl TE, Gartner JC, Zitelli BJ, Malatack JJ, Shaw BW, Iwatsuki S, van Thiel DH (1986) Cyclosporine absorption following orthotopic liver transplantation. J Clin Pharmacol 26: 647–651Google Scholar
  11. 11.
    Kahan BD, Kramer WG, Wideman C, Flechner SM, Lorber ML, van Buren CT (1986) Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 41: 459–464Google Scholar
  12. 12.
    Tufveson G, Odlind B, Sjöberg O, Lindberg A, Gabrielsson J, Lindström B, Lithell H, Selinus I, Töttermann T, Wahlberg J (1986) A longitudinal study of the pharmacokinetics of cyclosporine A and in vitro lymphocyte responses in renal transplantation. Transplant Proc 18: 16–24Google Scholar
  13. 13.
    Grevel J, Nüesch E, Abisch E, Kutz K (1986) Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects. Eur J Clin Pharmacol 31: 211–216Google Scholar
  14. 14.
    Henricsson S (1987) A new method for measuring the free fraction of cyclosporin in plasma by equilibrium dialysis. J Pharm Pharmacol 39: 384–385Google Scholar
  15. 15.
    Hows JM, Smith JM (1983) In vitro stability of cyclosporin? J Clin Pathol 36: 720–721Google Scholar
  16. 16.
    Hamilton G, Roth E, Wallisch E, Tichy F (1985) Semi-automated high-performance liquid chromatographic determination of cyclosporine A in whole blood using one-step sample purification and column-switching. J Chromatogr 341: 411–419Google Scholar
  17. 17.
    Ericzon BG, Todo S, Lynch I, Kam I, Pfachcinski RJ, Burkkart GJ, van Thiel DH, Starzl TE, Venkataramanan R (1987) Role of bile salts on cyclosporine absorption in dogs. Transplant Proc 19 no. 1: 1248–1249Google Scholar
  18. 18.
    Andrews W, Iwatsuki S, Starzl TE (1985) Correspondence. Transplantation 39: 338Google Scholar
  19. 19.
    Venkataramanan R, Burckart GJ, Ptachcinski RJ (1985) Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation. Semin Liver Dis 5: 357–368Google Scholar
  20. 20.
    Burckart GJ, Starzl TE, Venkataramanan R, Hashim H, Wong L, Wang P, Makowka L, Zeevi A, Ptachcinski RJ, Knapp JE, Iwatsuki S, Esquivel C, Sanghvi A, van Thiel DH (1986) Excretion of cyclosporine and its metabolites in human bile. Transplant Proc 18, no.6 [Suppl 5]: 46–49Google Scholar
  21. 21.
    Grahnén A (1985) The impact of time-dependent phenomena on bioequivalence studies. In: Breimer DD, Speiser P (eds) Topics in pharmaceutical sciences. Elsevier, Amsterdam, pp 179–190Google Scholar
  22. 22.
    Gammans RE, Mackenthun AV, Russell JW (1984) Comparative bioavailability of trazodone formulations using stable isotope methodology. Br J Clin Pharmacol 18: 431–437Google Scholar
  23. 23.
    Grahnén A, Hammarlund M, Lundqvist T (1984) Implications of intraindividual variability in bioavailability studies of furosemide. Eur J Clin Pharmacol 27: 595–602Google Scholar
  24. 24.
    Schrogie JJ, Davies RO, Hwang SS, Hesney M, Breault GO, Kwan KC, Huber PB, Feinberg JA, Abrams WB, Zinny MA (1979) Intrasubject variability in methyldopa bioavailability. Clin Pharmacol Ther 25: 248Google Scholar
  25. 25.
    Alván G, Siwers B, Vessman J (1977) Pharmacokinetics of oxazepam in healthy volunteers. Acta Pharmacol Toxicol 40: 40–51Google Scholar
  26. 26.
    Alvares AP, Kappas A, Eiseman JL, Anderson KE, Pantuck CB, Pantuck EJ, Hsiao K-C, Garland WA, Conney AH (1979) Intraindividual variation in drug disposition. Clin Pharmacol Ther 26: 407–419Google Scholar
  27. 27.
    Reed CR, Schwartz HJ (1984) Lack of influence of an intensive antacid regimen on theophylline bioavailability. J Pharmacokinet Biopharm 12: 315–331Google Scholar
  28. 28.
    Lemaire M, Tillement JP (1982) Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol 34: 715–718Google Scholar
  29. 29.
    Lithell H, Odlind B, Selinus I, Lindberg A, Lindström B, Frödin L (1986) Is plasma lipoprotein pattern of importance for treatment with cyclosporine? Transplant Proc 18, no. 1: 50–51Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • A. Lindholm
    • 1
    • 2
  • S. Henricsson
    • 1
  • M. Lind
    • 1
  • R. Dahlqvist
    • 1
  1. 1.Department of Clinical PharmacologyHuddinge HospitalHuddingeSweden
  2. 2.Department of Transplantation Surgery, Karolinska InstituteHuddinge HospitalHuddingeSweden

Personalised recommendations